iShares Russell 1000
Most Recent
Uber Closes above $45 for the First Time while Lyft Stock Rallies
After closing above its May 10 IPO listing price of $45 for the first time yesterday, Uber (UBER) was up 4% today. Can the rally last?
Soros Fund Management’s Top Buys in the Fourth Quarter
George Soros added 2.026 million shares of the SPDR Select Sector Fund (XLF) to its portfolio during the fourth quarter, giving it a weight of 1.5% in the portfolio.
Tesla’s Q4 Deliveries and Production Data: What to Expect
Tesla (TSLA) has been one of the handful of positive-return-yielding stocks in the fourth quarter so far.
Elon Musk Smartly Retains Power while Meeting SEC Obligations
Musk seems to have found ways to retain power while meeting the SEC’s obligatory measures at the same time. Let’s take a closer look.
Tesla: Analyst Predicts Solid Future Demand for Model 3
Wedbush Securities analyst Dan Ives expects Tesla Model 3 demand to remain “very strong into 2019 and beyond.”
This Elon Musk Tweet Shows One Reason Why Investors Love Tesla
Tesla has lost about 9.8% month-to-date as of December 27.
Are Tesla Short-Sellers Enjoying Elon Musk’s Silence?
December is proving to be underwhelming for Tesla investors (IWB).
Elon Musk Lists Rival Electric Vehicles on Twitter—NIO, GM, Ford
Before Tesla, many automakers launched limited-production electric models only to discontinue them soon after.
What Wall Street Says about Weatherford International
On December 26, 2017, 78% of the Wall Street analysts tracking Weatherford International rated it a “buy” or some equivalent.
Wall Street’s Call on Weatherford International
In this article, we’ll look Wall Street’s call and target price for Weatherford International (WFT) on September 12.
National Oilwell Varco’s Outlook for 3Q17
Does National Oilwell management see a recovery in 2017? National Oilwell Varco (NOV) management identified strong US onshore activity and weak offshore energy exploration and production activity as the drivers behind its changing revenue mix in 2Q17. In the company’s 2Q17 conference call, chairman and CEO Clay C. Williams stated that “much of our business […]
Why Was Baker Hughes’s Free Cash Flow Negative in 2Q17?
Baker Hughes’s (BHGE) CFO (cash from operating activities) remained negative in 2Q17, continuing its negative cash flow trend in 1Q17.
Inside Baker Hughes’s Growth Drivers in 2Q17
Baker Hughes’s (BHGE) North America segment saw 16.5% higher revenues from 2Q16 to 2Q17.
What Are NOV’s Challenges and Opportunities in 2Q17?
National Oilwell Varco’s (NOV) management expressed concern over upstream energy companies’ lower capex spending, which is negative for the oilfield services companies.
What’s Wall Street’s Take on Weatherford as of June 7?
In this article, we’ll look Wall Street analysts’ recommendations for Weatherford International (WFT) as of June 7, 2017.
What’s Schlumberger’s Net Debt after 1Q17?
Schlumberger’s (SLB) net debt rose 65% in 1Q17—compared to 1Q16. Its net debt was ~$11.7 billion in 1Q17.
How Medtronic’s CVG Segment Performed in Fiscal 4Q17
Medtronic (MDT) reported ~$7.9 billion in worldwide revenues in fiscal 4Q17.
BSX’s Resonate ICD and CRT-D Defibrillators Get US Approval
On May 9, 2017, Boston Scientific (BSX) announced the FDA approval of its Resonate family of products, including its ICD and CRT-D systems.
Analyzing National Oilwell Varco’s Net Debt after 1Q17
National Oilwell Varco’s (NOV) net debt increased 4% in 1Q17 over 1Q16. Its net debt amounted to ~$1.7 billion in 1Q17.
National Oilwell Varco’s Growth Prospects in 2017
National Oilwell Varco’s (NOV) management identified the requirement for rig upgrades for the small and large upstream players.
Will National Oilwell Varco’s Returns Rise after 1Q17?
Let’s take a look at some of the projects that could affect National Oilwell Varco’s (NOV) returns going forward.
Analyzing National Oilwell Varco’s Debt—A 2% Year-over-Year Fall
National Oilwell Varco’s (NOV) total debt decreased ~18% in 4Q16 over 4Q15. Its cash and marketable securities decreased 31% during the same period.
National Oilwell Varco’s Growth Prospects in 2017
National Oilwell Varco’s (NOV) management expects upstream activity in North America’s shale plays to improve in 2017.
Analysts’ Recommendations for Weatherford International
On March 1, ~71% of the analysts tracking Weatherford International rated it as a “buy,” ~20% rated it as a “hold,” and the rest rated it as a “sell.”
These Factors Could Improve AMAT’s Profitability in 2017
For fiscal 1Q17, AMAT expects its non-GAAP (generally accepted accounting principles) gross margin to rise 43.8% from 43.7% in fiscal 4Q16.
Can AbbVie’s Anti-Tau Therapeutics Help Late-Stage Alzheimer’s Patients?
Unlike Biogen (BIIB) and Eli Lilly, who have focused their attention on amyloid-beta based therapeutics, AbbVie (ABBV) is reluctant to enter this field.
AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017
AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.
Understanding Medtronic’s Weak CVG Segment Performance in Fiscal 2Q17
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.6 billion came from Medtronic’s CVG segment, representing ~35% of the company total.
Clinical Trial Data Shows Efficacy of Elagolix to Treat Uterine Fibroids
Together, AbbVie (ABBV) and Neurocrine Biosciences (NBIX) aim to develop Elagolix as a minimally invasive yet effective therapy for uterine fibroids
AnacorAcquisition Added Crisaborole to Pfizer’s Portfolio
On June 24, 2016, Pfizer (PFE) announced that it had completed the acquisition of Anacor Pharmaceuticals for a total net value of $5.2 billion. The acquisition added crisaborole.
What’s National Oilwell Varco’s Historical Valuation?
On September 30, 2016, National Oilwell Varco’s (NOV) share price was 10% higher compared to December 31, 2015.
Is National Oilwell Varco’s Net Debt Falling?
National Oilwell Varco’s (NOV) net debt (total debt less cash & marketable securities) fell 20% in 3Q15.
National Oilwell Varco’s Growth Prospects in 4Q16 and 2017
National Oilwell Varco’s (NOV) management expects most of the upstream recovery in North America to take place in 2H17.
How Do Amgen’s Valuation Multiples Compare to Its Peers’?
Since January 2015, Amgen has traded at a premium to Gilead Sciences (GILD) but at a significant discount to peers Biogen (BIIB) and Celgene (CELG).
Bill Gross: Monetary Policy on Steady but Slow Path
After the release of the FOMC’s November statement, Bill Gross said that monetary policy in the United States is steadily moving toward normalization, though its pace is slow.
Analysts’ Recommendations for Amgen and Its Peers in 2016
In the first nine months of 2016, Amgen witnessed strong volume growth for its key products such as Xgeva, Prolia, Nplate, Vectibix, and Sensipar.
Talazoparib and Pidilizumab May Prove Complementary to Pfizer’s Existing Oncology Drugs
Medivation has added its robust research pipeline with two promising investigational drugs, Talazoparib and Pidilizumab, to Pfizer’s oncology portfolio.
New Data Affirm Benefits of Medtronic’s Valiant Captivia
On September 20, 2016, Medtronic posted its new safety and efficacy data for its Valiant Captivia Thoracic Stent Graft System.
Boston Scientific’s Lotus Edge Valve System Gets Approval in Europe
Boston Scientific (BSX) is consistently working towards gaining higher market share in the attractive TAVR (transcatheter aortic valve replacement) market in Europe.
Bristol-Myers Squibb’s Role in the Multiple Myeloma Market
Bristol-Myers Squibb’s and AbbVie’s multiple myeloma drug Empliciti, combined with Celgene’s Revlimid and dexamethasone, received approval from the FDA.
How PPG’s Valuations Compare to Its Peers
As of August 26, 2016, PPG Industries was trading at a one-year forward PE multiple of 16.0x compared to Sherwin-Williams and Valspar at 21.20x and 20.30x, respectively.
Recommended Reading: Bernstein’s ‘Charts for the Beach’
According to Richard Bernstein, the five charts in the recent edition of his newsletter are “five of our favorite charts that highlight what we think consensus is currently missing.”
How Late-Stage Asset Rova-T Could Become a Leading Therapy
AbbVie (ABBV) expects to file a biologics license application for Rova-T as a third-line therapy for small cell lung cancer (or SCLC) in 2017.
Did the Brexit Vote Impact TJX’s International Sales in Fiscal 2Q17?
TJX Companies anticipates its TJX Canada segment to deliver same-store sales growth of 7%–8% in fiscal 2017 and sales of $3.1 billion–$3.2 billion.
Gilead’s Profit Margin Squeezed by Drop in Hepatitis C Drug Sales
Gilead Sciences reported diluted earnings per share (or EPS) of about $3.08 in 2Q16, which is a year-over-year (or YoY) decline of 2.2%.
Why Even a Good Jobs Report Couldn’t Cause Yields to Rise
We could see fewer jobs added going forward. If this trend continues, bond (AGG) (BND) yields could most likely stay low.
What Will Be a Key Driver of Biogen’s Future Valuations?
Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).
How Central Banks ‘Create’ Inflation
A QE program doesn’t just create inflation; it causes asset prices to rise as well. After the financial crisis of 2008, the Fed resorted to an ultra-accommodative monetary policy.
How Does APD Compare to Its Peers ahead of Fiscal 3Q16?
As of July 22, 2016, Air Products and Chemicals (APD) was trading at a one-year forward PE multiple of 18.8x compared to its peers Praxair and FMC.
How Did JNJ’s Medical Devices Business Fare in 2Q16?
Johnson & Johnson (JNJ) registered sales of approximately $6.4 billion in its Medical Devices business in 2Q16.
Beauty Companies Saw Mixed Inventory Levels in 1Q16
Estée Lauder (EL) ended calendar 1Q16 with a 3.5% rise in inventory.
JNJ Is Restructuring Its Medical Devices Business: What of 2Q16?
A robust pipeline and strong R&D (research and development) capabilities are expected to drive significant revenue growth for JNJ’s Medical Devices segment.
Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.
Can Amazon’s Re-Entry in the Smartphone Arena Pay Off?
Amazon (AMZN), in order to keep its Prime membership popular, is offering two unlocked Android smartphones exclusively priced for Prime members.
Will Restructuring Push Micron Back to Profitability?
As part of its restructuring initiative, Micron would only focus on critical projects and cut 2,400 jobs.
What Drove Constellation Brands’ Fiscal 1Q17 Margin Growth?
In fiscal 1Q17, which ended on May 31, 2016, Constellation Brands’ gross margin increased significantly to 47.1% from 45.2% in fiscal 1Q16.
Which Gaming Franchises Are Expected to Drive Revenues for TTWO?
Take-Two Interactive Software’s (TTWO) most successful franchise, Grand Theft Auto (or GTA), has sold over 235 million units worldwide.
What Drives Medtronic’s Restorative Therapies Group’s Growth?
Medtronic’s (MDT) Restorative Therapies Group (or RTG) segment, formed around seven years ago, has a strong market position today.
Qualcomm Is Bringing LTE to Battery-Powered IoT Devices
Recently, Qualcomm launched an LTE (long-term evolution) modems for battery-powered IoT devices to increase their communication range.
Are We in a Bear Market? Jeffrey Gundlach Weighs In
When asked about a bear market, Gundlach took the opportunity to present some numbers. Currently, he’s in capital preservation mode.
Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities
Now in its phase-1 clinical trial, AbbVie’s PF-06647020, an ADC targeting protein kinase 7 could become a major therapy for advanced solid tumors.
What Is the Strategy behind Cypress-Broadcom’s All-Cash Deal?
During Cypress’s fiscal 1Q16 earnings call, CEO Thurman John Rodgers explained that Broadcom offloaded the wireless IoT segment for two reasons.
Intel to Leverage Its Product Portfolio to Tap IoT Growth
IoT has a huge potential to create value for technology firms in the form of hardware, software, services, and integration.
What Is Analog Devices’ Acquisition Strategy?
Analog Devices (ADI) has been using M&A (mergers and acquisitions) to rapidly expand its technology offerings and boost its revenue.
Self-Driving Cars Could Mean Big Growth Opportunities for NXPI
A key semicond trend is likely to intensify as the automotive market progresses toward self-driving cars.
How Do NXP’s Cash and Debt Look after the Merger with Freescale?
The company’s debt burden rose after it raised new debt to fund its $12 billion acquisition of Freescale. It also took on Freescale’s debt burden.
Inside Xilinx’s Lead over Altera in the 20- and 16-Nanometer Markets
As Xilinx increases its share in the PLD market, a key will be its success in the long term is its competitive positioning compared to rival Altera.
Automotive: The Next Big Thing for Texas Instruments
Texas Instruments (TXN) has increased its exposure in the automotive, industrial, and communications segments, which accounted for 64% of the company’s revenue in fiscal 1Q16.
Corporate Profits Are Key for Richard Bernstein
Richard Bernstein spoke with CNBC’s Michael Santoli about what drives stock markets. He noted that his firm employs a top-down, macro research approach.
Understanding Boston Scientific’s MedSurg Segment
Boston Scientific’s (BSX) MedSurg segment contributes around 33% to the company’s total revenues and is the company’s second-largest segment.
Celgene Continues to Develop New Multiple Myeloma Drugs
Celgene has been working on its immunomodulatory backbone drugs to develop combination therapies for use in treating all lines of multiple myeloma.
Why Did Analysts Lower Estimates for Papa John’s after 1Q16 Results?
With same-store sales growth being lowered, it is expected that Papa John’s (PZZA) EPS will also be revised downward.
Why SanDisk Returned to Growth after a Year of Revenue Declines
In fiscal 1Q16, SanDisk’s (SNDK) revenue rose 3% YoY, topping analysts’ estimate and its own guidance. This was the first growth after four consecutive quarters of decline.
How AbbVie Plans to Strengthen Its Position in Oncology
On April 28, 2016, AbbVie (ABBV) announced its plans to acquire Stemcentrx. The deal is expected to be completed at a consideration of about $5.8 billion.
Understanding Intel’s Strong Margins amid Slow Revenue Growth
In fiscal 1Q16, Intel’s non-GAAP revenues rose by 8% YoY to $13.8 billion, missing the analyst estimate of $13.83 billion, which was a conservative one.
Why Intel’s 1Q16 Earnings Suggest All Is Not Well
Although Intel (INTC) reported revenue growth across all major business segments, it missed the analyst revenue estimate by $30 million.
Behind OptumHealth’s and OptumInsight’s Strong Revenue Growth in 1Q16
UnitedHealth Group’s healthcare delivery business, OptumHealth, managed to earn $4 billion revenues in 1Q16, which represents a YoY growth of about 22%.
Analyst Recommendations for Kinder Morgan: ‘Buy’ or ‘Hold’?
In this part of the series, we’ll look at what Wall Street analysts recommend for Kinder Morgan (KMI).
Why Did Kinder Morgan Lower Its 2016 EBITDA and Capex Guidance?
Kinder Morgan (KMI) announced a reduction in 2016 EBITDA and distributable cash flow guidance by 3% and 4%, respectively.
What Could Impact the Success of AMD’s Zen Core the Most?
With Zen, AMD looks poised to regain some share in the server and PC processor market. The question that remains is twofold: how much, and for how long?
Did Sprint Improve Its Network Reliability in Atlanta?
According to a Root Metrics report, Sprint’s position in the network reliability parameter improved two notches from its score in 2H15.
Behind Micron’s Product Enablement Plan for 3D XPoint
Micron and Intel have developed 3D XPoint in a way that benefits from both DRAM (dynamic random access memory) and NAND (negative AND).
Why Ready-to-Drink Coffee Is Gaining Popularity with US Consumers
Coffee lovers in the United States are boosting ready-to-drink coffee volumes.
Marlboro: The Star in Philip Morris’s Portfolio of Brands
Generally recognized as the world’s best-selling international cigarette, Marlboro accounted for 33.7% of the company’s total shipment volume in 2015.
Amgen’s Neupogen and Neulasta: Why Are They Losing Market Share?
Amgen expects Neupogen to lose market share in 2016. In 2015, Neupogen lost 3% market share in the United States due to biosimilar competition and branded competition.
Labor Market Growth Is Unlikely to Sustain Its Recent Momentum
The pace of recent job and wage growth indicates that the labor market remained weak despite a decline in the unemployment rate. The labor force participation rate has not increased substantially in recent years with the improvement in the economy.
How Will Celgene Grow Otezla’s Revenues in 2016?
Celgene (CELG) expects Otezla to attain blockbuster therapy status by earning about $1 billion in revenues for 2016. In 2015, the drug managed to earn revenues of about $471.7 million.
AT&T’s Valuation Metrics in the Global Telecommunication Market
As of March 11, 2016, AT&T was the largest global telecommunication player by market capitalization.
Still Beverages: A Key Focus for Nonalcoholic Beverage Companies
Still beverage volumes gained strength in 4Q15 as consumers continued to shift from sugary soda beverages to healthier options.
Why Warren Buffett Strongly Believes in the American Dream
Buffett said that it has been a terrible mistake to bet against America, not only for the past 240 years but even now. He believes that America’s emphasis on innovation and strength in commerce will continue to provide strong gains for its people.
What Could the VMware Deal Do for IBM’s Position in the Hybrid Cloud Space?
With this partnership, approximately 80% of companies that run VMware’s vSphere can be shifted to IBM’s cloud.
Innovations in Immunology Segment Could Boost AbbVie’s Valuations
AbbVie (ABBV) has been actively expanding Humira’s label and expects to earn annual revenues worth $18 billion from the sales of the drug in 2020.
What’s Really Driving Atmel’s Stock Volatility?
Atmel has a PE (price-to-equity) ratio of 80.3, which is way higher than Intel’s (INTC) 12.9, Texas Instrument’s (TXN) 18.19, and Microchip’s (MCHP) 26.9.
JCPenney’s Stock Rises by 14.7% on 4Q15 Earnings Beat
JCPenney’s earnings were ahead of the consensus Wall Street analysts’ estimate of $0.21 per share.
Monster’s American Fruits & Flavors Acquisition: Key Benefits
In a 4Q15 conference call on February 25, Monster Beverage’s (MNST) chair and chief executive officer, Rodney Cyril Sacks, discussed a proposed acquisition of the California-based American Fruits & Flavors.
Why PepsiCo’s Productivity Measures Helped Its 4Q15 Margins
PepsiCo (PEP) reported a gross margin of 54.9% in 4Q15, which ended December 26, 2015, up from 53.1% in the comparable quarter of the previous year.
The Lowe’s-Rona Transaction: Sizing Up the Potential Synergies
Lowe’s (LOW) expects the Rona (RON.TO) transaction to be accretive to its earnings per share or EPS from the very first year after the acquisition.
IBM is Pursuing Acquisitions to Push its Strategic Imperatives
Despite IBM’s Strategic Imperatives’ double-digit growth, IBM has been unable to post any revenue growth in the last 15 consecutive quarters. As a result, IBM’s stock touched a five-year low in late 2015.
IBM Plans to Tap the $105 Billion Cloud Video Market with Ustream
Ustream is likely to boost IBM’s Strategic Imperatives segment, which relates to IBM’s investment in cloud, analytics, mobile, social, and security technologies.
AT&T’s Mexican Wireless Operations: Solid Growth in 4Q15
In 4Q15, AT&T’s revenue from its Mexican wireless component was ~$643 million. That was a ~10.7% revenue growth on a sequential basis.